UOC
CRNX icon

UBS O'Connor’s Crinetics Pharmaceuticals CRNX Stock Holding History

UBS O'Connor’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-39,978
Closed -$1.15M – 323
2025
Q2 		$1.15M Sell
39,978
-635
-2% -$19.6K 0.03% 197
2025
Q1 		$1.36M Buy
40,613
+12,926
+47% +$483K 0.03% 157
2024
Q4 		$1.42M Buy
27,687
+2,994
+12% +$168K 0.04% 201
2024
Q3 		$1.26M Sell
24,693
-428
-2% -$22.1K 0.03% 250
2024
Q2 		$1.13M Buy
25,121
+19,100
+317% +$882K 0.03% 279
2024
Q1 		$282K Sell
6,021
-4,017
-40% -$157K 0.01% 374
2023
Q4 		$357K Sell
10,038
-16,115
-62% -$494K 0.01% 380
2023
Q3 		$778K Sell
26,153
-30,000
-53% -$618K 0.01% 358
2023
Q2 		$1.01M Buy
56,153
+22,732
+68% +$453K 0.02% 383
2023
Q1 		$537K Buy
+33,421
New +$619K 0.01% 460
2022
Q4 		– Sell
-90,460
Closed -$1.78M – 78
2022
Q3 		$1.78M Buy
90,460
+3,000
+3% +$61.2K 0.02% 658
2022
Q2 		$1.63M Buy
+87,460
New +$1.75M 0.02% 693

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return